Abstract
The epidermal growth factor receptor (EGFR) is a membrane-anchored, 170 kDa, protein tyrosine kinase that has been implicated in tumorigenesis. Recent sequence data from the publicly funded Human Genome Project has led to a revision in the structure of the EGFR gene, as well as an improved understanding of its mutations in tumor cells. The exons and introns of the EGFR gene are contained within 168 kilobases of DNA, including a completely sequenced 123-kilobase first intron. The EGFR gene is frequently amplified and rearranged in malignant gliomas with expression of oncogenic deletion (DM) and tandem duplication (TDM) mutants. The most common mutant is EGFRvIII, which arises from recombination between introns 1 and 7 with deletion of intervening sequences. Some human gliomas express 185 kDa and 190 kDa EGFR tandem duplication mutants with constitutive functional activity. These tumors contain EGFR genes with an in-frame tandem duplication of exons 18 through 25 or exons 18 through 26 respectively. Th e TDM also arise from recombination between flanking introns 17 and either 25 or 26. DM and TDM have been found in the same tumors, suggesting that the mechanisms responsible for both types of mutants may be closely related. Each of the introns involved in tumor-specific recombination contain sequences with homology to the recombination signal sequence (RSS) heptamers present in the V(D)J region of the immunoglobulin and T lymphocyte antigen receptor genes. These observations suggest a possible mechanism for oncogenic EGFR gene recombination in malignant gliomas.
Current Genomics
Title: Structure of the Epidermal Growth Factor Receptor Gene and Intron Recombination in Human Gliomas
Volume: 4 Issue: 1
Author(s): Michael J. Ciesielski and Robert A. Fenstermaker
Affiliation:
Abstract: The epidermal growth factor receptor (EGFR) is a membrane-anchored, 170 kDa, protein tyrosine kinase that has been implicated in tumorigenesis. Recent sequence data from the publicly funded Human Genome Project has led to a revision in the structure of the EGFR gene, as well as an improved understanding of its mutations in tumor cells. The exons and introns of the EGFR gene are contained within 168 kilobases of DNA, including a completely sequenced 123-kilobase first intron. The EGFR gene is frequently amplified and rearranged in malignant gliomas with expression of oncogenic deletion (DM) and tandem duplication (TDM) mutants. The most common mutant is EGFRvIII, which arises from recombination between introns 1 and 7 with deletion of intervening sequences. Some human gliomas express 185 kDa and 190 kDa EGFR tandem duplication mutants with constitutive functional activity. These tumors contain EGFR genes with an in-frame tandem duplication of exons 18 through 25 or exons 18 through 26 respectively. Th e TDM also arise from recombination between flanking introns 17 and either 25 or 26. DM and TDM have been found in the same tumors, suggesting that the mechanisms responsible for both types of mutants may be closely related. Each of the introns involved in tumor-specific recombination contain sequences with homology to the recombination signal sequence (RSS) heptamers present in the V(D)J region of the immunoglobulin and T lymphocyte antigen receptor genes. These observations suggest a possible mechanism for oncogenic EGFR gene recombination in malignant gliomas.
Export Options
About this article
Cite this article as:
Ciesielski J. Michael and Fenstermaker A. Robert, Structure of the Epidermal Growth Factor Receptor Gene and Intron Recombination in Human Gliomas, Current Genomics 2003; 4 (1) . https://dx.doi.org/10.2174/1389202033350092
DOI https://dx.doi.org/10.2174/1389202033350092 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets Cancer and Aids: New Trends in Drug Design and Chemotherapy
Current Computer-Aided Drug Design Signal Transduction Pathways and Transcriptional Mechanisms as Targets for Prevention of Emergence of Multidrug Resistance in Human Cancer Cells
Current Drug Targets Anti-Cancer Therapy: Targeting the Mevalonate Pathway
Current Cancer Drug Targets Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design Human Cytomegalovirus US28: A Functionally Selective Chemokine Binding Receptor
Infectious Disorders - Drug Targets Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Hemichannels in the Neurovascular Unit and White Matter Under Normal and Inflamed Conditions
CNS & Neurological Disorders - Drug Targets Advances of Bioinformatics Applied to Development and Evaluation of Boron-Containing Compounds
Current Organic Chemistry Nanosized Drug Delivery Systems for Direct Nose to Brain Targeting: A Review
Recent Patents on Drug Delivery & Formulation Recent Advances in Receptor-Targeted Fluorescent Probes for In Vivo Cancer Imaging
Current Medicinal Chemistry Super Water-Repellent Surfaces: Potential Application to Drag Reduction of Yachts
Recent Patents on Materials Science Overview of Angiogenesis and the use of Bevacizumab in Patients with Malignant Gliomas
Current Signal Transduction Therapy Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in Medicinal Chemistry and Pharmaceutical Technology- Strategies for Drug Delivery to the Brain
Current Topics in Medicinal Chemistry In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome
Recent Patents on Anti-Cancer Drug Discovery Pigment Epithelium-Derived Factor Prevents Melanoma Growth via Angiogenesis Inhibition
Current Pharmaceutical Design